These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26288226)

  • 21. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients.
    Guthoff M; Berger K; Althaus K; Mühlbacher T; Bakchoul T; Steurer W; Nadalin S; Königsrainer A; Heyne N
    BMC Nephrol; 2020 May; 21(1):178. PubMed ID: 32404066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial.
    Margreiter R; Klempnauer J; Neuhaus P; Muehlbacher F; Boesmueller C; Calne RY
    Am J Transplant; 2008 Jul; 8(7):1480-5. PubMed ID: 18510632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results.
    Kaufman DB; Leventhal JR; Gallon LG; Parker MA
    Am J Transplant; 2006 Feb; 6(2):331-9. PubMed ID: 16426317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression.
    Lee D; Keymeulen B; Hilbrands R; Ling Z; Van de Velde U; Jacobs-Tulleneers-Thevissen D; Maleux G; Lapauw B; Crenier L; De Block C; Mathieu C; Pipeleers D; Gillard P
    Transplantation; 2017 Sep; 101(9):2218-2227. PubMed ID: 27779572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Kupin W; Rosen A; Cordovilla T; Tueros L; Herrada E; Miller J
    Clin Transplant; 2008; 22(2):200-10. PubMed ID: 18339140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved metabolic control and quality of life in seven patients with type 1 diabetes following islet after kidney transplantation.
    Cure P; Pileggi A; Froud T; Messinger S; Faradji RN; Baidal DA; Cardani R; Curry A; Poggioli R; Pugliese A; Betancourt A; Esquenazi V; Ciancio G; Selvaggi G; Burke GW; Ricordi C; Alejandro R
    Transplantation; 2008 Mar; 85(6):801-12. PubMed ID: 18360260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience.
    Hirshberg B; Rother KI; Digon BJ; Lee J; Gaglia JL; Hines K; Read EJ; Chang R; Wood BJ; Harlan DM
    Diabetes Care; 2003 Dec; 26(12):3288-95. PubMed ID: 14633816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience.
    Froud T; Ricordi C; Baidal DA; Hafiz MM; Ponte G; Cure P; Pileggi A; Poggioli R; Ichii H; Khan A; Ferreira JV; Pugliese A; Esquenazi VV; Kenyon NS; Alejandro R
    Am J Transplant; 2005 Aug; 5(8):2037-46. PubMed ID: 15996257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
    Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
    Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of steroid-free low concentration calcineurin inhibitor maintenance immunosuppression regimen on renal allograft histopathology and function.
    Nainani N; Patel N; Tahir N; Kumar R; Weber-Shrikant E; Gundroo AA; Murray BM; Tornatore KM; Blessios GA; Venuto RC
    Nephrol Dial Transplant; 2012 May; 27(5):2077-83. PubMed ID: 22058172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study.
    Jaksch P; Ankersmit J; Scheed A; Kocher A; Muraközy G; Klepetko W; Lang G
    Am J Transplant; 2014 Aug; 14(8):1839-45. PubMed ID: 25039364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
    Watson CJ; Bradley JA; Friend PJ; Firth J; Taylor CJ; Bradley JR; Smith KG; Thiru S; Jamieson NV; Hale G; Waldmann H; Calne R
    Am J Transplant; 2005 Jun; 5(6):1347-53. PubMed ID: 15888040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alemtuzumab induction in deceased donor kidney transplantation.
    Huang E; Cho YW; Hayashi R; Bunnapradist S
    Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab.
    Ciancio G; Sageshima J; Akpinar E; Gaynor JJ; Chen L; Zarak A; Hanson L; Tueros L; Guerra G; Mattiazzi A; Kupin W; Roth D; Ricordi C; Burke GW
    Transplantation; 2013 Nov; 96(9):800-6. PubMed ID: 23903014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.
    Tan HP; Kaczorowski DJ; Basu A; Unruh M; McCauley J; Wu C; Donaldson J; Dvorchik I; Kayler L; Marcos A; Randhawa P; Smetanka C; Starzl TE; Shapiro R
    Am J Transplant; 2006 Oct; 6(10):2409-17. PubMed ID: 16889606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.
    Farney A; Sundberg A; Moore P; Hartmann E; Rogers J; Doares W; Jarrett A; Adams P; Stratta R
    Clin Transplant; 2008; 22(1):41-9. PubMed ID: 18217904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.